ESI Group at the Farnborough International Airshow 2022
18.7.2022 09:00:00 EEST | Business Wire | Press release
Regulatory News:
ESI Group (ISIN Code: FR0004110310, Symbol: ESI) (Paris:ESI) , a global simulation and virtual prototyping software partner for the industry, will be present at the Farnborough International Airshow (18 and 22 July 2022). ESI Group will present an outline of aircraft Acoustics for both interior and exterior noise. Besides, The Group will illustrate how virtual reality solutions help power industry 4.0, showcasing and demonstrating its solution for human-centric virtual simulation and collaborative work with IC.IDO.
2 software solutions presented:
- ESI’s flagship Virtual Reality software IC.IDO for human-centric process validation and product integration: facilitating agile design processes, robust manufacturing, and safe maintenance operations.
- ESI’s vibro-acoustics software VA ONE for aircraft interiors and electric aircraft like eVTOL concepts: meeting interior noise level comfort and optimizing exterior noise impact in urban areas
Promising progress in the aircraft industry thanks to digitalization and virtual reality
Digitalization plays a major role in developing sustainable aviation, hydrogen planes, electric aircraft, urban mobility, eVTOLs... Virtual reality helps industries achieve sustainability goals, to secure “first time right”, reduce costs, time and go to market. Throughout the years, Virtual reality upgraded processes, allowing faster turnaround for foundries and composite parts manufacturers, lower scrap rates, manufacturability despite new geometries. Industrials have been able to achieve their desired vibro-acoustic performance and virtually pre-certified products. Besides, the need for physical try-outs and prototypes significantly decreased, paving the way to more efficient assembly steps, increased productivity and output, reduced maintenance costs, and decreased industrial risks for operators.
ESI Group has been operating in the aircraft industry for the last decades. ESI’s aerospace customers leverage the benefits of virtual reality solutions, helping them achieve their goal to producing clean, safe, and productive.
eVTOLS: ESI Group helps foster innovations – interior external noise and comfort
ESI has the mission to help aerospace companies in gearing their digital transformation, to be a partner they can trust to help foster innovations, such as the eVTOLS, that will change the landscape of urban mobility. ESI Group is already helping the pioneers of that segment achieve their product performance and safety targets while meeting stringent noise regulations, reducing noise impact in urban areas and meeting interior aircraft noise comfort levels. ESI Group’s VA One software solution help manufacturers to predict and resolve potential noise and vibration challenges in very early stages of their development process. Thus, meeting safety standards and their objectives for aircraft acoustics, and minimizing weight and controlling costs.
ESI Group’s software solutions for a clean, safe, and productive industry
1. Power systems manufacturer Rolls-Royce uses ESI casting simulation software ProCAST for Product-Process co-design and to collaborate more efficiently with their supply chain towards greater quality parts, avoiding late design changes and eliminating scrap rates in a more sustainable manner.
2. Saab Aerospace Systems relies on ESI composites manufacturing simulation software PAM-COMPOSITES to refine their injection strategies for the next generation aircraft doors, supporting the advanced manufacturing of ever lighter structures.
3. Latécoère counts on the advanced virtual reality capabilities provided by IC.IDO (1), to connect manufacturing engineering teams from around the world on the same virtual platform to secure “First Time Right” production and to train operators remotely, cutting down on travel emissions, yet providing a “learning by doing” approach.
(1) ESI Group at the exhibition: France Pavillion. ESI Group will be part of the GIFAS (& “AsTech”) area in HALL 1 – Booth 13.60 Village ASTech
About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high-stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world, and reported 2021 sales of €136.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
Follow ESI: LinkedIn | Facebook | Twitter | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220717005031/en/
Contact information
ESI Group
Florence Barré
press@esi-group.com
+33 1 49 78 28 28
Verbatee - Press & Shareholder Relations
Jérôme Goaer, j.goaer@verbatee.com, +33 6 61 61 79 34
Aline Besselièvre, a.besselievre@verbatee.com, +33 6 61 85 10 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
